Company Profile
Arbutus Stock Price, News & Catalysts
- Ticker:
- ABUS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Canada
Stock performance
4.71 USD (+0.86%)
Close
Last updated: August 17, 2026
842M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, ABUS closed up 0.86% at $4.71. No new same-company headline was identified in the current news window.
Company overview
Hepatitis B Therapeutics
Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B. Its current clinical strategy centers on suppressing viral antigen production with RNA interference.
Imdusiran
Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins, including surface antigen. Clinical studies have evaluated it alone and with immune-modulating agents to seek durable off-treatment control.
Phase 2b Strategy
Arbutus has aligned with the FDA on the design and safety parameters of a proposed Phase 2b study of imdusiran. The company is incorporating that feedback into the final clinical protocol.
LNP Intellectual Property
Arbutus retains economic interests in lipid nanoparticle intellectual property through Genevant and related licensing, settlement, and patent-enforcement activities. These rights are separate from its internal hepatitis B development program.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Arbutus (ABUS)?
Arbutus (ABUS) most recently closed at 4.71 USD, a +0.86% move versus the previous session.
What is the market cap of Arbutus (ABUS)?
Arbutus currently has a market capitalization of 842M USD on BioPharmSignal.
What does Arbutus do?
Hepatitis B Therapeutics Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B. Its current clinical strategy centers on suppressing viral antigen production with RNA interference. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins, including surface...
On which exchange is ABUS stock listed?
Arbutus (ABUS) is associated with NASDAQ, Canada, Biopharma.
What is Hepatitis?
Hepatitis B Therapeutics Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B.
Which conditions is Arbutus targeting with Hepatitis?
Hepatitis B Therapeutics Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B. Its current clinical strategy centers on suppressing viral antigen production with RNA interference. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins, including surface...
What is Therapeutics?
Hepatitis B Therapeutics Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B.
What is Arbutus?
Hepatitis B Therapeutics Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B.